Day One Biopharmaceuticals to Host Q3 2024 Earnings Call
Day One Biopharmaceuticals (NASDAQ: DAWN) is gearing up to share its financial results for the third quarter of 2024. The company, dedicated to crafting targeted therapies for severe medical conditions affecting individuals of all ages, is known for its innovation in pediatric cancer treatment. They have scheduled a live conference call and webcast on the day of the announcement to discuss their performance and progress during the quarter.
What to Expect from the Upcoming Webcast
The highly anticipated conference call will take place on a Wednesday afternoon at 4:30 PM ET. Participants can expect a thorough overview of the company's financial results alongside exciting developments in their research and treatment pipelines. The live audio of the event promises to be accessible on their Investors & Media page, catering to those interested in the latest from Day One.
Archiving the Webcast for Future Reference
After the live event, an archived version of the webcast will remain available for a limited period, ensuring that stakeholders and interested parties can revisit the critical details shared during the presentation. This approach signifies Day One's commitment to transparency and communication with its investors.
About Day One Biopharmaceuticals: A Commitment to Pediatric Oncology
Founded from a clear mission to improve outcomes for children with cancer, Day One Biopharmaceuticals places a strong emphasis on addressing the significant gaps in pediatric cancer therapy development. The company's initiatives aim to transform the landscape of cancer treatment, ensuring that patients and their families receive better options right from the start of their journey.
Innovative Treatments in the Pipeline
With a promising portfolio that includes tovorafenib (OJEMDA™) and the ongoing development of DAY301 and a VRK1 inhibitor program, Day One is actively working alongside leading oncologists, scientists, and families. Their collaborative approach ensures that they are identifying critical needs and addressing them with potent, targeted therapies.
Why Pediatric Cancer Awareness is Critical
Pediatric cancer remains a challenging field, often lacking the necessary research investment. Day One takes a stand to ensure that the voices of parents and affected children are heard, infusing their developmental process with insights and experiences that directly inform therapeutic advancements.
Engaging with the Community
Through constant interaction with the oncology community and families, Day One works to create a better understanding of the unique challenges faced by pediatric cancer patients. Their focus extends beyond mere drug development; it's about reshaping the conversation around pediatric cancer to ensure patients receive comprehensive care.
Investor Relations: Staying Informed
For those looking to stay updated on Day One Biopharmaceuticals, the company utilizes a variety of platforms, including their Investor Relations website and social media handles. Through these channels, they share important news, upcoming events, and updates regarding their financial performance, reinforcing their commitment to transparency and engagement.
Contact Information for Investor and Media Inquiries
Those interested in learning more can reach out to Day One’s media team or investor relations representatives. The company encourages open communication, making it easier for stakeholders to access the information they need.
Frequently Asked Questions
What is Day One Biopharmaceuticals focused on?
Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric cancer and other serious diseases.
When will the Q3 2024 financial results be announced?
The Q3 2024 financial results will be reported during a live conference call on October 30, 2024, at 4:30 PM ET.
How can I access the webcast for the financial results?
The live audio of the webcast will be available on Day One's Investors & Media page.
Is there a recording of the conference call available?
Yes, an archived version of the conference call will be accessible on their website for 30 days after the event.
Who can I contact for more information about Day One Biopharmaceuticals?
For media inquiries, you can reach Laura Cooper, and for investor-related questions, please contact PJ Kelleher.
